ArticleEJNMMI research2026
FAPi-PET/CT as surrogate marker for subclinical myocardial fibrosis is a prognostic tool for patients undergoing left-sided heart valve surgery.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate fibroblast activation protein (FAP)-targeted positron emission tomography and computed tomography (PET/CT) imaging as surrogate marker for cardiac fibrosis and therefore as prognostic tool for patients with left-sided valvular heart disease undergoing open-heart surgery.
resultsIn 13 patients (6 men, 7 women; mean age ± SD, 62 ± 13 years) scheduled for aortic and/or mitral valve surgery (aortic, n = 3; mitral, n = 9; both, n = 1) preoperative FAPi-PET/CT ([68Ga]Ga-RTX1363S) was perfomred. FAP-positive volume and FAP uptake was quantified by different methods (isocontour with fixed and variable threshold) and correlated to preoperative clinical parameters, including (left ventricular ejection fraction (LVEF) and serum N-terminal prohormone of brain natriuretic peptide (NT-proBNP), as well as to changes in LVEF from preoperatively to 3–6 months follow-up (available for n = 11 patients). FAP-uptake in the left ventricular (LV) myocardium was highly variable in the study cohort. Isocontour-55%-based FAP-positive volume was found to correlate statistically significantly with preoperative LVEF (p = 0.03) and preoperative NT-proBNP (p = 0.02). In addition, we found a significant correlation with the change in LVEF from preoperatively to 3–6 months follow-up examination (p = 0.04).
conclusionsPreoperative FAPi PET/CT seems to have potential to predict LVEF changes after valvular heart surgery and may therefore be an important tool for risk stratification of asymptomatic patients with left-sided valvular heart disease to support the appropriate timing of valvular surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.